Coherus Oncology
CHRS
176 hedge funds and large institutions have $572M invested in Coherus Oncology in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 53 reducing their positions, and 27 closing their positions.
534% more call options, than puts
Call options by funds: $3.17M | Put options by funds: $499K
40% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 53
3.53% more ownership
Funds ownership: 98.39% → 101.92% (+3.5%)
4% less funds holding
Funds holding: 183 → 176 (-7)
11% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 27
42% less capital invested
Capital invested by funds: $981M → $572M (-$409M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.37M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.73M |
| 4 |
BlackRock
New York
|
+$7.05M |
| 5 |
TLP
Tri Locum Partners
New York
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$9.13M |
| 2 |
Swedbank
Stockholm,
Sweden
|
-$6.97M |
| 3 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$6.06M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.98M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$3.14M |
CHRS Hedge Fund Activity: Q2 2022 in Review
176 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2022, worth a combined $572M — down 42% from $981M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CHRS and 24 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 74 added.
The largest buyer was State Street, adding an estimated $10.6M. The largest seller was Perceptive Advisors, cutting an estimated $9.13M.
- 176 institutional investors held Coherus Oncology (CHRS) as of Q2 2022, down from 183 in Q1 2022.
- Funds reported $572M of Coherus Oncology stock for Q2 2022, down 42% quarter-over-quarter.
- 24 funds opened new Coherus Oncology positions in Q2 2022 and 27 closed out, a net change of -3 holders.
- The largest Coherus Oncology buyer in Q2 2022 was State Street, an estimated $10.6M added.
- The largest Coherus Oncology seller in Q2 2022 was Perceptive Advisors, an estimated $9.13M sold.
Based on aggregated 13F filings for Q2 2022.